Portal de Periódicos da CAPES

CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma

2017; Karger Publishers; Volume: 24; Issue: 3 Linguagem: Inglês

10.1159/000452691

2341-4545

Rosa Coelho, Marco Silva, Eduardo Rodrigues‐Pinto, Hélder Cardoso, Susana Lopes, Pedro Pereira, Filipe Vilas‐Boas, João Santos‐Antunes, José Costa‐Maia, Guilherme Macedo,

Gallbladder and Bile Duct Disorders

Cholangiocarcinoma is the second most frequent primitive liver malignancy and is responsible for 3% of the malignant gastrointestinal neoplasms. The aims of this study were to determine the association of serum levels of CA 19-9 at diagnosis with other clinical data and serum liver function tests and to identify possible factors that influence the survival rates during follow-up.Retrospective observational study of 89 patients with a diagnosis of cholangiocarcinoma followed at the Department of Gastroenterology during 5 years. Statistical analyses were performed using SPSS version 20.0.Patients were followed up for a median time of 127 days (IQR: 48-564), and the median age at diagnosis was 71.0 years (IQR: 62.0-77.5). The median survival rate was 14.0 months (IQR: 4.3-23.7), and the mortality rate was 79%. Patients with CA 19-9 levels ≥103 U/L had lower albumin levels and higher levels of alanine aminotransferase and γ-glutamyltransferase. CA 19-9 levels ≥103 U/L were associated with a higher probability of metastization (p = 0.001) and lower rates of treatment with curative intent (p = 0.024). In a multivariate analysis, CA 19-9 levels <103 U/L and surgery were independent predictors of survival.Predictive factors for overall survival were identified, namely presence of metastasis, surgery, and chemotherapy. CA 19-9 levels ≥103 U/L were predictive factors for survival and metastization.